Synthesis and pharmacokinetic and pharmacodynamic evaluation of the forodesine HCl analog BCX-3040

Nucleosides, Nucleotides and Nucleic Acids

Volumn 24, Issue 10-12, 2005, Pages 1817-1830

  Kezar III, Hollis S ^a   Kilpatrick, J Michael ^a   Phillips, Deborah ^a   Kellogg, Debbie ^a   Zhang, Jianwen ^a   Morris Jr , Philip E ^a  

^a BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Forodesine HCl; PNP; Purine nucleoside phosphorylase; T cell

Indexed keywords

ANTINEOPLASTIC AGENT; BCX 3040; FORODESINE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG SYNTHESIS; PHARMACOLOGICAL PARAMETERS;

ADMINISTRATION, ORAL; ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HEXOSAMINES; INJECTIONS, INTRAVENOUS; LEUKEMIA; LYMPHOMA; MALE; PURINE-NUCLEOSIDE PHOSPHORYLASE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 29244480032     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770500267246     Document Type: Article

References (16)

1. Thomas, D.A.; Wierda, W.; Faderl, S.; O'Brien, S.; Kornblau, S.; Koller, C.; Bantia, S.; Kilpatrick, J.M.; Bennett, J.C.; Kantarjian, H.; Gandi, V. Preliminary activity of intravenous BCX-1777 in aggressive T-cell malignancies. Blood 2003, 102, 4772.
2. Kilpatrick, J.M.; Harman, L.; Phillips, D.; Zhang, J.; Morris P.E., Jr.; Bukowski, R.; Thomas, D.A. Intravenous and oral pharmacodynamic study of BCX-1777, a novel purine nucloeoside phosphorylase transition-state inhibitor. FASEB J. 2004, 18, B254.
3. Furman, R.R.; Gandhi, V.; Thomas, D.A.; Bennett, J.C.; Bantia, S.; Kilpatrick, J.M. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphyorylase (PNP) inhibitor, demonstrates clinical activity in phase I/II studies in patients with B-cell acute lymphoblastic leukemia. Blood 2004, 104, 2743.
4. Isola, L.; Furman, R.R.; Thomas, D.A.; Gandhi, V.; Bennett, J.C.; Bantia, S.; Kilpatrick, J.M. Antileukemic activity and pharmacodynamics of intravenous forodesine (BCX-1777), a novel purine nucleoside phosphorylase (PNP) inhibitor, in phase I/II trials in patients with advanced T-cell malignancies. Blood 2004, 104, 4501.
5. Duvic, M.; Foss, F.; Olsen, F.A.; Forero-Torres, J.A.; Bennett, J.C.; Bantia, S.; Kilpatrick, J.M. Intravenous forodesine (BCX-1777), a novel purine nucleoside phosphoylase (PNP) inhibitor, demonstrates clinical activity in patients with refractory cutaneous T-cell lymphoma. Blood 2004, 104, 2491.
6. Stoeckler, J.D. Purine nucleoside phosphorylase: A target for chemotherapy. In Developments in Cancer Chemotherapy; Glazer, R.I., Ed.; CRC Press: Boca Raton, FL, 1984.
7. Markert, M.L. Purine nucleoside phosphorylase deficiency. Immunodeficiency Rev. 1991, 3, 45.
8. Cory, J.G.; Cory, A.H. Inhibitors of Ribonucleotide Diphosphate Reductase Activity, Pergamon Press: New York, 1989.
9. Morris, P.E.; Montgomery, J.A. Inhibitors of the enzyme purine nucleoside phosphoryolase. Expert Opinion Therapeutic Patents, 1998, 8(3), 283.
10. Bantia, S.; Kilpatrick, J.M. Purine nucleoside phosphorylase inhibitors in T-cell malignancies. Current Opinion in Drug Discovery and Development 2004, 2, 243.
11. Bantia, S.; Miller, P.J.; Parker, C.; Ananth, S.L.; Horn, L.L.; Kilpatrick, J.M.; Morris, P.E., Jr.; Hutchison, T.L.; Montgomery, J.A.; Sandhu, J.S. Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H) - A novel potent and orally active immunosuppressive agent. International Immunopharmacology 2001, 1, 1199.
12. Morris, P.E.; Omura, G.A. Inhibitors of the enzyme purine nucleoside phosphorylase as potential therapy for psoriasis. Current Pharmaceutical Design, 2000, 6, 943.
13. Miles, R.W.; Tyler, P.C.; Furneaux, R.H.; Bagdassarian, C.K.; Schramm, V.L. One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry, 1998, 37, 13147.
14. Kilpatrick, J.M.; Morris, P.E., Jr.; Scrota, D.G., Jr.; Phillips, D.; Moore, D.R., II; Bennett, J.C.; Babu, Y.S. Intravenous and oral pharmaceokinetics study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor. In vivo effects on blood 2′-deoxyguanosine in primates. International Immunopharmacology 2003, 3/4, 541.
15. Evans, G.B.; Fumeaux, R.H.; Hutchison, T.L.; Kezar, H.S., III; Morris, P.E.; Schramm, V.L.; Tyler, P.C. Addition of lithiated 9-deazapurine derivatives to a carbohydrate cyclic imine: Convergent synthesis of the aza-C-nucleoside immucillins. Journal of Organic Chemistry, 2001, 66, 5723.
16. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research, 1993, 10, 1093.